Concepedia

Mohammed A. Aleskandarany

MA

71

Publications

4K

Citations

37

H-Index

2004

Active since

Affiliations

University of Nottingham(Current)

Nottingham University Hospitals NHS Trust

Menoufia University

Nottingham City Hospital

Nottingham Trent University

Mohammed A. Aleskandarany is an author at University of Nottingham specializing in medicine, breast cancer, and cell biology.

ORCID

Top concepts

Publications per year

2004–2020

71

Publications

71

Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes

Emad A. Rakha, Somaia Elsheikh, Mohammed A. Aleskandarany et al. · Clinical Cancer Research · 2009 · 479 citations

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen

Hany Onsy Habashy, Desmond G. Powe, Cindy M. Staka et al. · Breast Cancer Research and Treatment · 2009 · 235 citations · Full text

, , +9

CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome

Somaia Elsheikh, Andrew R. Green, Mohammed A. Aleskandarany et al. · Breast Cancer Research and Treatment · 2007 · 155 citations

, , +8

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer

Mohammed A. Aleskandarany, Andrew R. Green, Ahmed Benhasouna et al. · Breast Cancer Research · 2012 · 126 citations · Full text

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours

Andrew R. Green, Mohammed A. Aleskandarany, Devika Agarwal et al. · British Journal of Cancer · 2016 · 123 citations · Full text

Rows per page

1–5 of 71